This phase II trial studies how well ibrutinib and blinatumomab work in treating patients
with B acute lymphoblastic leukemia that has come back or is not responding to treatment.
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer
cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating
patients with relapsed or refractory B acute lymphoblastic leukemia.
I. To evaluate the efficacy of ibrutinib and blinatumomab in patients with relapsed or
refractory B acute lymphoblastic leukemia (B-ALL) as measured by complete response (CR) rate.
I. To further examine the efficacy and safety of ibrutinib and blinatumomab in patients with
relapsed or refractory B-ALL as measured by overall response rate (ORR, defined as CR plus CR
with incomplete count recovery [CRi]), relapse free survival (RFS), overall survival (OS),
minimal residual disease (MRD) response, proportion of patients bridged to allogeneic
hematopoietic cell transplant (allo-HCT), and toxicity.
Philadelphia Chromosome Positive, Adult B Acute Lymphoblastic Leukemia
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.